GPBAR1 and neoplasm: Despite the lack of direct evidence linking BAs to tumor vaccines efficacy, emerging evidence suggests their potential role in modulating anti-tumor immunity through multifaceted mechanisms: BAs activate FXR and TGR5 on DCs, altering antigen-presenting capacity and cytokine secretion profiles (e.g. reduced IL-12 and elevated IL-10) [125].